Veklury Still Keeping Gilead Above Water Amid Pandemic, Patent Expiries
HIV, Hepatitis Continue To See Sales Declines
Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.
You may also be interested in...
Gilead Sees HIV Business Return To Sales Growth As Oncology Gets Boost
The company said screening and diagnosis were still below pre-pandemic levels, but Biktarvy and Descovy brought HIV sales back into positive territory.
COVID-19 Products Had Strong 2021, But Omicron Casts Shadow Over 2022
Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.
Coronavirus Update: With New Data, Don’t Count J&J Out Yet
J&J announced strong data for its single-shot vaccine, with even stronger booster shot data to boot. Also Gilead posted strong results for outpatient use of Veklury, but it faces stiff competition, while Clover announced new data and Pfizer/BioNTech sold another 500 million vaccine doses for donation.